Immunovant Inc. (IMVT)
NasdaqGS: IMVT
· Цена в реальном времени · USD
41.18
-0.64 (-1.53%)
На закрытии: Aug 14, 2026, 10:24 AM
Описание компании
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant Inc.
| Страна | United States |
| Дата IPO | 21 июн. 2019 г. |
| Отрасль | Biotechnology |
| Сектор | Healthcare |
| Сотрудники | 315 |
| CEO | Dr. Eric Venker M.D., Pharm.D. |
Контакты
Адрес: 1000 Park Forty Plaza Durham, NC United States | |
| Сайт | https://immunovant.com |
Данные по акции
| Тикер | IMVT |
| Биржа | NasdaqGS |
| Финансовый год | Apr '25 - Mar '26 |
| Валюта отчётности | USD |
| Код CIK | 0001764013 |
| Номер CUSIP | n/a |
| Номер ISIN | n/a |
| Employer ID | n/a |
| Код SIC | n/a |
Ключевые руководители
| Имя | Должность |
|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director |
| Mr. Tiago M. Girao CPA | Chief Financial Officer |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Christine Blodgett | Senior Vice President of Human Resources |
| Ms. Becky Merlina | Senior VP & Global Head of Quality |
| Ms. Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management |
| Ms. Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development |